Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or South Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to South Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. South Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Lisa Sauls (NPI 1275099954)

Field	Value
Entity Type	Individual
Organization	Lisa Sauls
Address	600 N Wheeler Ave
City	Prosperity
State	SC
ZIP	29127
Taxonomy	Family Nurse Practitioner
NPI Enumerated	February 18, 2019

Payer Source	Total Paid
Medicare	$3.4M
Medicaid	$0

Key Findings

Provider profile and payer footprint: LISA SAULS (Family Nurse Practitioner) has been NPI-enumerated since 2019-02-18 (~7 years ago) and reports $3.4M in lifetime Medicare revenue while having no Medicaid billing on file, making this an effectively single-payer (Medicare) billing profile. The absence of Medicaid claims suggests limited participation in state Medicaid networks or that the practice’s patient mix is concentrated in Medicare-eligible populations.

Revenue concentration around a few biologics: this provider’s top three Medicare codes — J2357 (11.8% of Medicare revenue), J3245 (11.7%), and J2350 (11.3%) — together account for 34.8% of total Medicare revenue, indicating a material revenue concentration in a small number of high-cost injectable biologics. That concentration highlights dependence on continued utilization and reimbursement for these specific agents.

Service-line implications from code mix: the dominant codes (J2357, J3245, J2350) and multiple additional J-codes for monoclonal antibodies and immune globulins indicate an operational focus on in-office administration of specialty biologic injections and infusions rather than routine primary-care visits. The mix (omalizumab, tildrakizumab, ocrelizumab and several immune globulin products) is consistent with a specialty infusion/injection practice model that relies on biologic drug administration workflows and associated infusion staffing.

Infusion and administration capacity is evident: the presence of infusion administration and chemotherapy/infusion add-on codes such as 96365, 96366, 96413, and 96415 alongside many J-codes demonstrates that this provider bills for initial and subsequent IV infusion services and chemotherapy/infusion-related administration. Those administration codes — including 96365 at $15.9K revenue and 96366 at $5K revenue — support the conclusion that the practice delivers in-office IV/infusion services rather than only dispensing self-administered drugs.

Competitive standing is mixed across top drugs: for the largest single-code revenue driver J2357 ($393.3K) this provider ranks #46 of 581 nationally (92th percentile), reflecting a relatively strong national presence for omalizumab administration; by contrast, J3245 ($392.4K) ranks #116 of 225 (46th percentile) and J2350 ($378K) ranks #82 of 105 (22th percentile), indicating more modest or below-average national volume for those agents. Across the broader J-code set the provider shows pockets of higher percentile presence (for example J0517 at the 83th percentile) alongside many codes where volume is typical or modest, which suggests niche strength rather than broad-market dominance.

Notable statistical outliers in utilization: the injection administration code 96372 is flagged as "notably above typical national volume" and appears at the 98th percentile (648 claims, $5.8K revenue), signalling unusually high throughput of intramuscular/subcutaneous injections relative to peers. Conversely, some J-codes show extremely low national standing (for example J0129 at #1210 of 1221, 1th percentile), underscoring that high-volume activity is concentrated in a subset of drugs rather than across the board.

Operational and contracting implications: with $3.4M in Medicare revenue concentrated in specialty biologics and no Medicaid revenue, the practice is likely exposed to Medicare reimbursement policy and formulary/coverage changes for those agents. The code mix also implies operational dependencies — inventory, infusion staff, and payer arrangements for high-cost injectables — that would be material considerations for payers or downstream contracting partners evaluating network inclusion or risk.

Growth and risk signals relative to tenure: being enumerated ~7 years ago and achieving $3.4M in Medicare revenue suggests a developed mid-sized specialty infusion/injection operation rather than a nascent clinic. However, the lack of Medicaid billing on file represents both a growth opportunity (state programs) and a concentration risk (single-payer dependence) if Medicare reimbursement or utilization shifts materially.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

30 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J2357	Injection, omalizumab, 5 mg	13,110	$30	$393.3K
J3245	Injection, tildrakizumab, 1 mg	3,600	$110	$392.4K
J2350	Injection, ocrelizumab, 1 mg	8,400	$50	$378K
J0517	Injection, benralizumab, 1 mg	2,280	$130	$301K
J3380	Injection, vedolizumab, intravenous, 1 mg	14,400	$20	$244.8K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	6,310	$40	$220.8K
J0897	Injection, denosumab, 1 mg	9,180	$20	$165.2K
J2182	Injection, mepolizumab, 1 mg	7,100	$20	$163.3K
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	3,890	$40	$143.8K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	5,400	$30	$140.4K

Showing 1–10 of 30

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 30 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. South Carolina Distribution

Lisa Sauls — 1 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — South Carolina

Full comparison — all codes billed, vs. state median

30 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J2350	7	10	10,800	$40	$546.8K
J3245	9	20	3,800	$110	$435.3K
J0129	44	40	9,640	$30	$424.2K
J3380	7	20	11,400	$20	$231K
J2323	3	10	8,700	$20	$211.9K
J9312	17	20	2,340	$60	$193.7K
J2357	4	30	4,360	$30	$183.8K
J0517	3	20	1,100	$130	$180.6K
J1569	3	20	3,860	$40	$161.4K
J1568	5	10	5,220	$30	$155.1K

Showing 1–10 of 30

Related Providers

Other providers that share a Tax Identification Number (TIN) with Lisa Sauls, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Palmetto Infusion Services LLC	SC	Infusion Therapy Clinic/Center	$0	$93.6M
Sc House Calls Inc	SC	Family Medicine Physician	$0	$11.6M
Kristi Hunter	GA	General Practice Physician	$6.4M	$0
Rachel Tedesco	NC	Nurse Practitioner	$5.7M	$0
Stephen Parks	SC	Family Medicine Physician	$3.9M	$0
Lindsay Gamble	SC	Family Nurse Practitioner	$3.7M	$0
Rosalee Unwin	SC	Family Nurse Practitioner	$2.9M	$0
Whitley Weatherford	SC	Family Nurse Practitioner	$2.7M	$0
Joel Waldrop	SC	Emergency Medicine Physician	$2.4M	$9.3K
Andrew Donato	SC	Emergency Medicine Physician	$2.3M	$8.9K

Nearby Providers

Other providers in the same ZIP code as Lisa Sauls, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Lovelace Family Medicine, PA	SC	Primary Care Clinic/Center	$0	$1.7M
Oscar Lovelace	SC	Family Medicine Physician	$460.7K	$0
Spencer Lovelace	SC	Family Medicine Physician	$398.9K	$0
William Dixon	SC	Family Medicine Physician	$296.3K	$0
Corbett Toussaint	SC	Podiatrist	$71.5K	$0

Lisa Sauls — Billing Profile & Reimbursement Data

Sign up for Lisa Sauls — Billing Profile & Reimbursement Data policy alerts

Lisa Sauls — Billing Profile & Reimbursement Data

Sign up for Lisa Sauls — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References